Caris Life Sciences said Thursday it is partnering with genomic and health data software company GenoSpace to advance personalized medicine for cancer care.
Caris will use GenoSpace’s analytics systems to glean insights from Caris Molecular Intelligence, a tumor profiling service. The Irving, Texas company will also use GenoSpace analytics to unlock treatment insights from its registry of clinicopathologic and outcome variables. The registry includes data on more than 65, 000 patients whose tumors underwent multitechnology profiling by Caris.
The resulting analysis will create a HIPAA-compliant informatics platform that gives Caris’ institutional partners the ability to search institution-specific data for their own research goals.
The collaboration will also make it easier for Caris to isolate critical drug-biomarker associations, providing better treatment information to oncologists and their patients, the company said. — Kellen Owings
Subscribe to Devices & Diagnostics Letter for complete coverage of the medical devices industry. Click here for more information.
